---
document_datetime: 2023-09-21 21:29:35
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tookad-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: tookad-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.1653718
conversion_datetime: 2025-12-19 12:07:01.695781
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## TOOKAD

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                           |
|----------------------|----------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------|
| IAIN/0020            | A.1 - Administrative change - Change in the name and/or address of the MAH | 07/12/2022                          |                                             | SmPC, Labelling and PL           |                                                                                                                   |
| R/0019               | Renewal of the marketing authorisation.                                    | 21/07/2022                          | 26/09/2022                                  | SmPC, Annex II and PL            | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |          | TOOKAD in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.        |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10654 /202111 | Periodic Safety Update EU Single assessment - padeliporfin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/06/2022 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                         |
| IA/0018/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                        | 14/02/2022 | n/a        |          |                                                                                                                                                           |
| II/0015             | Submission of the Clinical Study Report for Category 1 study: Post-authorisation efficacy study (PAES) CLIN1001 PCM301FU5, A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD Soluble for Localised Prostate Cancer compared to Active Surveillance. The Annex II has been updated to remove reference to this study. The RMP version 8.0 is approved. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated | 10/02/2022 | 21/06/2022 | Annex II | The Clinical Study Report for Category 1 study CLIN1001 PCM301FU5 has been submitted and the Annex II has been updated to remove reference to this study. |

<div style=\"page-break-after: always\"></div>

|                     | by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                     |            |            |          |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| PSUSA/10654 /202105 | Periodic Safety Update EU Single assessment - padeliporfin                                                                                                                                                                                                                     | 02/12/2021 | n/a        |          | PRAC Recommendation - maintenance |
| PSUSA/10654 /202011 | Periodic Safety Update EU Single assessment - padeliporfin                                                                                                                                                                                                                     | 10/06/2021 | n/a        |          | PRAC Recommendation - maintenance |
| IB/0014             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                  | 25/05/2021 | 21/06/2022 | Annex II |                                   |
| IB/0011             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                  | 17/12/2020 | 04/02/2021 | Annex II |                                   |
| PSUSA/10654 /202005 | Periodic Safety Update EU Single assessment - padeliporfin                                                                                                                                                                                                                     | 26/11/2020 | n/a        |          | PRAC Recommendation - maintenance |
| IB/0008/G           | This was an application for a group of variations. B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation | 08/09/2020 | n/a        |          |                                   |
| IA/0010             | B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant                                                                                                                           | 07/09/2020 | n/a        |          |                                   |

<div style=\"page-break-after: always\"></div>

|                     | specification parameter (e.g. deletion of an obsolete parameter)                                                           |            |            |                 |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IB/0009             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                 | 12/08/2020 | n/a        |                 |                                   |
| IB/0007             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 12/08/2020 | n/a        |                 |                                   |
| PSUSA/10654 /201911 | Periodic Safety Update EU Single assessment - padeliporfin                                                                 | 11/06/2020 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0005           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 20/02/2020 | 04/02/2021 | Annex II and PL |                                   |
| PSUSA/10654 /201905 | Periodic Safety Update EU Single assessment - padeliporfin                                                                 | 28/11/2019 | n/a        |                 | PRAC Recommendation - maintenance |
| PSUSA/10654 /201811 | Periodic Safety Update EU Single assessment - padeliporfin                                                                 | 14/06/2019 | n/a        |                 | PRAC Recommendation - maintenance |
| PSUSA/10654 /201805 | Periodic Safety Update EU Single assessment - padeliporfin                                                                 | 29/11/2018 | n/a        |                 | PRAC Recommendation - maintenance |